Mitsui Global Investment logo

Mitsui Global Investment

North America, California, United States, Menlo Park

Description

Mitsui & Co. Global Investment (MGI) is the corporate venture capital arm of Mitsui & Co., Ltd., one of the world's largest and most diversified trading and investment companies, headquartered in Japan. While its parent company is based in Tokyo, MGI maintains a significant presence in the United States, with an office in Menlo Park, California, serving as a key hub for its North American investment activities. MGI focuses on identifying and investing in innovative early to growth-stage companies across various strategic sectors, aiming to leverage Mitsui's vast global network and business expertise to foster portfolio company growth.

MGI's investment thesis is deeply rooted in supporting technological advancements and business models that align with Mitsui's long-term strategic interests. The fund primarily targets companies in areas such as Information Technology (IT), healthcare, biotechnology, advanced materials, and clean energy. Beyond capital, MGI provides its portfolio companies with invaluable access to Mitsui's extensive global ecosystem, which includes diverse business units spanning energy, chemicals, machinery, food, infrastructure, and more. This strategic partnership approach helps startups accelerate market entry, expand internationally, and forge critical industry connections.

As a corporate venture fund, MGI's investment strategy often involves both financial returns and strategic synergies. The fund typically participates in initial rounds ranging from seed to Series C, with a focus on companies demonstrating strong potential for disruption and scalability. While specific check sizes can vary based on stage and strategic fit, MGI's initial investments generally fall within the range of $500,000 to $10,000,000. Over its operational history, MGI has made over 100 investments globally, demonstrating its active role in the venture ecosystem. The substantial backing from its parent company, Mitsui & Co., Ltd., which reported a net profit of approximately $6.5 billion for the fiscal year ending March 2023, underscores MGI's robust financial capacity and long-term commitment to its portfolio.

MGI plays a crucial role in Mitsui's broader innovation strategy, acting as a window into emerging technologies and market trends. By investing in promising startups, MGI not only aims for financial returns but also seeks to create new business opportunities and enhance the competitiveness of Mitsui's existing operations. Its disciplined yet flexible approach allows it to adapt to evolving market dynamics, making it a significant player in the global venture capital landscape, particularly for companies seeking strategic partners with deep industry ties.

Investor Profile

Mitsui Global Investment has backed more than 148 startups, with 2 new investments in the last 12 months alone. The firm has led 21 rounds, about 14% of its total and boasts 59 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series B, Series A rounds (top funding stages).
  • Majority of deals are located in United States, China, Israel.
  • Strong thematic focus on Biotechnology, Health Care, Software.
  • Typical check size: $500K – $10M.

Stage Focus

  • Series C (26%)
  • Series B (24%)
  • Series A (17%)
  • Series Unknown (14%)
  • Series D (11%)
  • Series E (3%)
  • Seed (2%)
  • Post Ipo Equity (1%)
  • Debt Financing (1%)
  • Private Equity (1%)

Country Focus

  • United States (73%)
  • China (7%)
  • Israel (4%)
  • Canada (3%)
  • United Kingdom (3%)
  • Japan (3%)
  • India (2%)
  • Singapore (1%)
  • Belgium (1%)
  • Indonesia (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Software
  • Manufacturing
  • Mobile
  • Medical
  • Wireless
  • Information Technology
  • Security
  • Internet
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Mitsui Global Investment frequently co-invest with?

Sequoia Capital
North America, California, United States, Menlo Park
Co-Investments: 5
Sofinnova Investments
North America, California, United States, Menlo Park
Co-Investments: 5
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 5
Kleiner Perkins
North America, California, United States, Menlo Park
Co-Investments: 9
Goldman Sachs
North America, New York, United States, New York
Co-Investments: 8
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 5
General Motors Ventures
North America, Michigan, United States, Warren
Co-Investments: 5
Walden International
North America, California, United States, San Francisco
Co-Investments: 5
Samsung Ventures
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 6
Intel Capital
North America, California, United States, Santa Clara
Co-Investments: 5

Which angels does Mitsui Global Investment often collaborate with?

CG
North America, Utah, United States, Salt Lake City
Shared Deals: 1
BB
North America, Utah, United States, Salt Lake City
Shared Deals: 1
JD
North America, California, United States, Palo Alto
Shared Deals: 1
AL
North America, Arizona, United States, Phoenix
Shared Deals: 1
PS
North America, Georgia, United States, Atlanta
Shared Deals: 1
CR
Europe, Bayern, Germany, Munich
Shared Deals: 1
SN
North America, Florida, United States, Miami
Shared Deals: 1
Boon Hwee Koh
Asia, Central Region, Singapore, Singapore
Shared Deals: 1
David Stern
North America, California, United States
Shared Deals: 1

What are some of recent deals done by Mitsui Global Investment?

Ellipsis Health

San Francisco, California, United States

Ellipsis Health is an AI healthcare company that offers vocal biomarker technology to assess behavioral health through speech.

Artificial Intelligence (AI)Health CareInformation TechnologySoftware
Series AJun 12, 2025
Amount Raised: $45,000,000
Stately Bio

Chicago, Illinois, United States

Stately Bio is the trade-off between measuring cells and keeping them alive.

Biotechnology
SeedMay 1, 2025
Amount Raised: $12,000,000
Reunion Neuroscience

Toronto, Ontario, Canada

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

BiotechnologyMental HealthPharmaceutical
Series AMay 2, 2024
Amount Raised: $103,000,000
Leash Biosciences

Salt Lake City, Utah, United States

Leash Biosciences engages in machine learning to solve medicinal chemistry.

Health CareMachine LearningMedical
SeedApr 5, 2024
Amount Raised: $9,300,000
QurAlis

Cambridge, Massachusetts, United States

QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.

BiotechnologyGeneticsHealth CarePrecision MedicineTherapeutics
Series BMar 9, 2023
Amount Raised: $88,000,000
QurAlis

Cambridge, Massachusetts, United States

QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.

BiotechnologyGeneticsHealth CarePrecision MedicineTherapeutics
Series AMay 13, 2020
Amount Raised: $42,000,000
Rallybio

Farmington, Connecticut, United States

Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.

BiopharmaBiotechnologyHealth CareTherapeutics
Series BApr 14, 2020
Amount Raised: $145,000,000
Anaeropharma Science

Tokyo, Tokyo, Japan

Anaeropharma is a biopharmaceutical company engaged in research and development.

BiopharmaBiotechnologyPharmaceuticalTherapeutics
Series UnknownJan 1, 2020
Spire Global

San Francisco, California, United States

Spire Global is a space to cloud data analytics company utilizing satellites to provide maritime, aviation, and weather tracking.

AnalyticsBig DataData IntegrationInformation ServicesInformation Technology
Series DSep 25, 2019
Amount Raised: $40,000,000
NapaJen

Burlingame, California, United States

NapaJen Pharma is a Pharmaceutical company designed to supply drugs in effective methods to end up active form in the organ.

BiotechnologyHealth CareMedicalPharmaceutical
Series CJan 9, 2019
Amount Raised: $12,400,000